ONCE-DAILY INGREZZA® (valbenazine) capsules

PATIENT ASSISTANCE PROGRAM

INBRACE® SUPPORT PROGRAM

APPLICATION

To be completed in full, signed, and dated, then faxed to 844-394-7155.
For additional assistance, call 84-INGREZZA (844-647-3992), 8 AM – 8 PM EST, M – F.

- Only completed INGREZZA Patient Assistance Program Applications will be reviewed for patient program eligibility. Please ensure all areas of the form are completed in full with all signatures.
- Applicants must reside in the continental US or its territories, meet the program financial requirements, and must not have prescription coverage for INGREZZA in order to qualify. Each applicant will be assessed for individual program eligibility upon receipt of this completed INGREZZA Patient Assistance Program Application.

1 PATIENT INFORMATION

First Name:	Last Name:		DOB: / /
Address:	City:	State:	ZIP:
Last 4 digits of the SSN:	US Resident: Yes ☐ No ☐	Gender: Male ☐ Female ☐	
Preferred Phone:	Mobile Phone? ☐ Yes ☐ No	Email:	
Alternate Contact/Care Partner:	Alt Contact/Care Partner Phone:		

Patient Signature: Date:

(Optional) Ship Prescription to: ☐ Care Partner ☐ HCP office

By signing here, I authorize the use and disclosure of my PHI as set forth in the HIPAA Authorization on page 3.

☐ **I consent to have my prescription shipped to preference above.**

2 PATIENT INSURANCE INFORMATION–Please attach a copy of the patient's insurance card (check below if no insurance)

☐ Patient does not have insurance.	**Medical Insurance Name:**	**Prescription Insurance Name:**
Phone:	Cardholder ID #:	Phone: / Cardholder ID #:
Policyholder Name & DOB: / /		BIN: / PCN:

3 FINANCIAL INFORMATION–If information is unavailable, INBRACE program specialists will contact the patient

Total Monthly Gross Household Income: $ | Household Size (select one): 1 ☐ 2 ☐ 3 ☐ 4 ☐ 5 ☐ 6 ☐

Select Your Sources of Income: Salary/Wages ☐ SS Pension/Unemployment ☐ Alimony/Child Support ☐ Retirement ☐ SSDI ☐ SSI ☐

No Household Income ☐ Other ☐: _____

Income subject to verification

4 CLINICAL INFORMATION

Primary Diagnosis Code Category: ☐ **Tardive Dyskinesia (G24.01)** ☐ Other diagnosis: | Allergies:

5 PRESCRIBER INFORMATION

Prescriber Name:			Prescriber NPI #:
Facility Name:			
Address:	City:	State:	ZIP:
Phone:	Fax:		
Office Contact Name:	Phone:	Fax:	Email Address:
Referring Pharmacy Name:	Address:		Phone:

6 PRESCRIPTION FOR INGREZZA (valbenazine) CAPSULES

PRESCRIPTION INSTRUCTIONS: Check <u>one</u> Rx box below.

☐ **Initial Rx with 80 mg Maintenance Rx**
40 mg once daily x 7 then
80 mg once daily x 23.
No refills.
80 mg once daily.
1-month supply. **Refills #____**

OR

☐ **Initial Rx with 40 mg Maintenance Rx**
40 mg once daily
1-month supply. **Refills #____**

OR

☐ **60 mg Maintenance Rx Only***
60 mg once daily
1-month supply. **Refills #____**

OR

☐ **80 mg Maintenance Rx Only***
80 mg once daily
1-month supply. **Refills #____**

☐ **Other Rx** Sig: _____ Quantity: _____ Other Rx Refills:____

*If 40 mg in-office samples were used, you may choose to select 60 mg or 80 mg Maintenance Rx Only.

7 PRESCRIBER CERTIFICATION

I certify that the information provided in this INGREZZA® (valbenazine) capsules Patient Assistance Program Application is complete and accurate to the best of my knowledge, I have prescribed INGREZZA based on my judgment of medical necessity, and I will supervise the patient's medical treatment. I certify that, where required by federal and/or state law, I have obtained my patient's written legal permission to share identifiable information with Neurocrine Biosciences, Inc. and the INBRACE Support Program Pharmacy. I authorize the forwarding of this prescription and information to the INBRACE Support Program Pharmacy. I understand that neither I nor the patient should seek reimbursement for any free or discounted product received under the program. The INGREZZA Patient Assistance Program requires the healthcare provider or facility to retain proof of patient income on file in their office. For purposes of an audit, the INGREZZA Patient Assistance Program could ask for a copy of the patient's IRS 1040 form or other proof of income. I agree to notify the service providers if I become aware at any time in the future of changes in my patient's circumstances that would affect his or her eligibility, including but not limited to changes in health insurance status or coverage, financial status, or United States residency status. I understand that Neurocrine Biosciences, Inc. reserves the right to change or terminate the INGREZZA Patient Assistance Program at any time.

Prescriber Signature: Date:

*(Original signature required - *If required by applicable law, please attach copies of all prescriptions on official state prescription forms)*

Please see Indication and Important Safety Information on page 2.

 CP-VBZ-US-0017v6 06/2021

Neurocrine BIOSCIENCES

IMPORTANT INFORMATION

INDICATION & USAGE

INGREZZA® (valbenazine) capsules is indicated for the treatment of adults with tardive dyskinesia.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

INGREZZA is contraindicated in patients with a history of hypersensitivity to valbenazine or any components of INGREZZA. Rash, urticaria, and reactions consistent with angioedema (e.g., swelling of the face, lips, and mouth) have been reported.

WARNINGS & PRECAUTIONS

Somnolence

INGREZZA can cause somnolence. Patients should not perform activities requiring mental alertness such as operating a motor vehicle or operating hazardous machinery until they know how they will be affected by INGREZZA.

QT Prolongation

INGREZZA may prolong the QT interval, although the degree of QT prolongation is not clinically significant at concentrations expected with recommended dosing. INGREZZA should be avoided in patients with congenital long QT syndrome or with arrhythmias associated with a prolonged QT interval. For patients at increased risk of a prolonged QT interval, assess the QT interval before increasing the dosage.

Parkinsonism

INGREZZA may cause parkinsonism in patients with tardive dyskinesia. Parkinsonism has also been observed with other VMAT2 inhibitors. Reduce the dose or discontinue INGREZZA treatment in patients who develop clinically significant parkinson-like signs or symptoms.

ADVERSE REACTIONS

The most common adverse reaction (≥5% and twice the rate of placebo) is somnolence. Other adverse reactions (≥2% and >placebo) include: anticholinergic effects, balance disorders/falls, headache, akathisia, vomiting, nausea, and arthralgia.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit MedWatch at www.fda.gov/medwatch or call 1-800-FDA-1088.

Please see accompanying INGREZZA full Prescribing Information

PATIENT HIPAA AUTHORIZATION FOR USE AND DISCLOSURE OF PROTECTED HEALTH INFORMATION

I authorize Neurocrine, companies working with Neurocrine, and my healthcare provider and pharmacy to use and disclose to Neurocrine, and companies working with Neurocrine, my Protected Health Information ("PHI"), for the following purposes (1) providing financial assistance options, (2) reimbursement support, (3) medication compliance and persistence, and (4) other treatment-related services, including providing information and materials related to such services (collectively called "Support Services"). I authorize the disclosure of my PHI to specific individuals who are identified on the INGREZZA Patient Assistance Program Application. I understand that the companies working with Neurocrine, including my pharmacy, may receive payment for the use and disclosure of my PHI. I understand that once it is disclosed, it may be re-disclosed by the recipient(s). After such a disclosure, the information may no longer be protected by HIPAA or the terms of this authorization against further redisclosure. I understand that this authorization shall continue in effect for a period of ten years unless a shorter period is required by law. I understand that I may revoke this authorization to use or disclose my PHI by contacting an INBRACE Support Program representative by telephone (844-647-3992) or by mailing a letter to Neurocrine, Attn: INBRACE Support Program, 12780 El Camino Real, San Diego, CA 92130. I understand that my healthcare provider, pharmacy, and/or Neurocrine will not condition my treatment on signing this Authorization. I can choose not to sign this Authorization. However, if I choose not to sign, Neurocrine will not be able to help me with Support Services as described above. I may obtain a copy of this Authorization.